Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan

Journal of the Renin-angiotensin-aldosterone System : JRAAS
Minamo OnoGenjiro Kimura

Abstract

It is known that reduced glomerular filtration rate (GFR) is a crucial factor to limit the blood pressure lowering effect of antihypertensives. In the present study, we tested whether the effects of monotherapy with an angiotensin receptor blocker (ARB) to lower proteinuria could be restricted by reduced GFR. Thirty-five renal patients who had albuminuria more than 30 mg/day, but did not have diabetic nephropathy or nephrotic syndrome, were studied before and during eight weeks of monotherapy with ARB, olmesartan. Blood pressure was lowered from 129 ± 18/79 ± 12 to 116 ± 18/72 ± 12 mmHg (p < 0.0001), while albuminuria was reduced from 614±630 to 343±472 mg/day (p < 0.0001). Albuminuria was inversely correlated with GFR both before and during treatment. Albuminuria reduction was enhanced as plasma renin activity (p = 0.047) and dose of olmesartan were increased (p = 0.04). Although the absolute reduction in proteinuria was not correlated with GFR (p = 0.56), the % reduction was significantly proportional with GFR (p = 0.027). Multiple regression analysis demonstrated that 64% of proteinuria reduction could be explained by baseline levels of albuminuria, GFR and renin activity. The reduction in proteinuria by olmesartan may be ro...Continue Reading

References

Jan 1, 1995·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R T GansevoortP E de Jong
Aug 28, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·M PragaM León
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Oct 3, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·D A PriceN K Hollenberg
Feb 4, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Kiyoshi KurokawaNobuya Ogawa
Jun 6, 2003·Kidney International·Barry M Brenner
Sep 19, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Alexander V CrowePeter S Williams
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jul 16, 2004·Kidney International·Elke WühlUNKNOWN ESCAPE Trial Group
Feb 3, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Robert C AtkinsEdmund J Lewis
Feb 5, 2008·British Journal of Clinical Pharmacology·Cornelis BoersmaUNKNOWN PREVEND Study Group
Jan 25, 2011·Journal of the American Society of Nephrology : JASN·François BerthouxLise Thibaudin
Mar 11, 2011·The New England Journal of Medicine·Hermann HallerUNKNOWN ROADMAP Trial Investigators

❮ Previous
Next ❯

Citations

Jun 15, 2012·Cardiovascular Diabetology·Yao-Chen ChuangKwang-Ming Fang
Mar 22, 2014·International Journal of Endocrinology·Vivian SoetiknoRianto Setiabudy

❮ Previous
Next ❯

Methods Mentioned

BETA
urine collection

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.